New York Methodist Hospital, Brooklyn, New York.
Cardiovascular Research Foundation, New York, New York; New York Presbyterian-Columbia University Medical Center, New York, New York.
JACC Cardiovasc Interv. 2016 Jul 25;9(14):1450-7. doi: 10.1016/j.jcin.2016.04.037. Epub 2016 Jun 29.
The aim of this study was to understand the impact of the timing of ischemic and hemorrhagic events after percutaneous coronary intervention (PCI) with drug-eluting stents on subsequent mortality.
These events have been strongly associated with subsequent death.
In the multicenter, prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug Eluting Stents) study, patients at 11 clinical sites with successful PCI with drug-eluting stents underwent assessment of platelet function and were followed for 2 years. Events occurring after PCI-definite or probable stent thrombosis (ST), myocardial infarction (MI) not related to ST, and clinically relevant bleeding (CB)-were classified as early (≤30 days), late (31 to 365 days), or very late (>365 days). Mortality within 30 days of each event was estimated by Kaplan-Meier methodology. Cox regression multivariate modeling was used to analyze the relationship between each event (as a time-updated variable) and mortality over the entire study period.
Among 8,582 patients, 1,060 (12.4%) had events-691 (8.1%) had CB, 294 (3.4%) had MI, and 75 (0.9%) had ST-and 7,522 (87.6%) had no events. The highest risk was associated with early ST (38.5% mortality at 30 days after the event), whereas very late MI (7.5%) and late CB (7.3%) were less dangerous. By multivariate analysis, each event was independently predictive of death, with hazard ratios of 2.4, 1.8, and 11.4, respectively (p < 0.0001).
Approximately 1 in 8 patients successfully undergoing PCI with drug-eluting stents had CB, MI, or ST during the ensuing 2 years. These events are associated with an increased hazard of mortality, particularly within the first 30 days following the event, warranting efforts to prevent their occurrence.
本研究旨在了解经皮冠状动脉介入治疗(PCI)后缺血和出血事件的发生时间对随后死亡率的影响。
这些事件与随后的死亡密切相关。
在多中心前瞻性 ADAPT-DES(药物洗脱支架双重抗血小板治疗评估)研究中,11 个临床中心成功接受药物洗脱支架 PCI 的患者进行了血小板功能评估,并随访 2 年。将 PCI 后确定或可能发生的支架血栓形成(ST)、与 ST 无关的心肌梗死(MI)和临床相关出血(CB)定义为早期(≤30 天)、晚期(31 至 365 天)或非常晚期(>365 天)。通过 Kaplan-Meier 方法估计每个事件后 30 天内的死亡率。使用 Cox 回归多变量模型分析每个事件(作为时间更新变量)与整个研究期间死亡率之间的关系。
在 8582 例患者中,1060 例(12.4%)发生事件-691 例(8.1%)发生 CB,294 例(3.4%)发生 MI,75 例(0.9%)发生 ST-7522 例(87.6%)未发生事件。风险最高的是早期 ST(事件后 30 天死亡率为 38.5%),而非常晚期 MI(7.5%)和晚期 CB(7.3%)的危险性较低。通过多变量分析,每个事件都是死亡的独立预测因素,危险比分别为 2.4、1.8 和 11.4(p<0.0001)。
大约每 8 例接受药物洗脱支架 PCI 的患者中,就有 1 例在随后的 2 年内发生 CB、MI 或 ST。这些事件与死亡率增加相关,尤其是在事件发生后的前 30 天内,需要努力预防其发生。